<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00687414</url>
  </required_header>
  <id_info>
    <org_study_id>2008-054 Protocol # 080311 AA</org_study_id>
    <nct_id>NCT00687414</nct_id>
  </id_info>
  <brief_title>Evaluation of Formin Gene Status and Expression in Myeloproliferative and Myelodysplastic Disorders</brief_title>
  <official_title>Evaluation of Formin Gene Status and Expression in Myeloproliferative and Myelodysplastic Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spectrum Health Hospitals</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Van Andel Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Community Foundation for Southeast Michigan (JP McCarthy Fund)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Spectrum Health Hospitals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of the study is to analyze the expression of genes and sequences encoding the human
      mammalian diaphanous (mDia) related formin proteins to test the hypothesis that defects in
      the mDia expression or function might drive the pathophysiology of myelodysplastic syndrome,
      acute myeloid leukemia and other myeloproliferative diseases.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Leukocytes and myeloid lineage cells from these specimens will be assayed for expression of
      DRF genes using standard molecular biological approaches to measure mRNA levels. Extracted
      DNA will be analyzed for mutations that affect expressions or function using direct
      sequencing techniques.

      Alternatively, expression of DRF gene products (mDia proteins) will be assessed using
      specific antibodies and flow cytometry. Molecular findings resulting from these assays will
      be correlated with clinical information recorded in specimen logbook.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>to determine if defective DRF1 expression or mDia1 function may contribute to myeloid malignancies and point to mDia1 as an attractive therapeutic target in MDS and MPS</measure>
    <time_frame>within a year</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Myeloproliferative Disorder</condition>
  <condition>MDS</condition>
  <condition>AML</condition>
  <arm_group>
    <arm_group_label>adults</arm_group_label>
    <description>male and female with MDS and MPD and AML</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy</arm_group_label>
    <description>Healthy control group</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      peripheral blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Community sample
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 and over

          -  Male

          -  Female

          -  Diagnosed with MDS, MPD and AML

        Exclusion Criteria:

          -  Under the age of 18

          -  Received bone marrow transplant

        Control Group Criteria:

        inclusion:

          -  healthy men and women

          -  â‰¥ 55 years of age

        exclusion:

          -  history of hematological condition

          -  history of cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arthur S Alberts, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Van Andel Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St Mary's Health Care</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Van Andel Research Institute</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2008</study_first_submitted>
  <study_first_submitted_qc>May 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2008</study_first_posted>
  <last_update_submitted>January 8, 2010</last_update_submitted>
  <last_update_submitted_qc>January 8, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2010</last_update_posted>
  <responsible_party>
    <name_title>Arthur S. Alberts, Ph.D.</name_title>
    <organization>Van Andel Research Institute</organization>
  </responsible_party>
  <keyword>gene expression</keyword>
  <keyword>gene sequencing</keyword>
  <keyword>gene encoding</keyword>
  <keyword>MPD</keyword>
  <keyword>MDS</keyword>
  <keyword>AML</keyword>
  <keyword>mDia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

